---
title: 'Continuously improving outcome over time after second allogeneic stem cell
  transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of
  1540 patients'
date: '2024-05-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38697960/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240503181600&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Second allogeneic stem cell transplantation (alloSCT2) is among the most
  effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT
  (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date
  outcome results and to identify factors for improved outcome. Among 1540 recipients
  of alloSCT2, increasing age, better disease control and performance status before
  alloSCT2, more use of alternative donors and higher conditioning intensity ...
disable_comments: true
---
Second allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome. Among 1540 recipients of alloSCT2, increasing age, better disease control and performance status before alloSCT2, more use of alternative donors and higher conditioning intensity ...